Washington, D.C., March 10, 2026 – The ERISA Industry Committee (ERIC) issued the following statement today regarding the Trump Administration’s announcement to make biosimilar development faster and more affordable. The statement can be attributed to ERIC President and CEO, James Gelfand.
“Biosimilars offer a safe, effective, and lower-cost alternative to brand-name biologic medications, yet a spate of overly complex requirements has created a regulatory morass that, for too long, has hindered both access and affordability. The Trump Administration action underscores the importance of accelerating access to biosimilars to provide affordable drug options for patients, employers, and health plans alike.
Since launching a data-driven research initiative more than five years ago, ERIC has consistently championed policies that promote competition and streamline processes to reduce drug spending for employer plans and their employees. The FDA’s new guidance to simplify and modernize the biosimilar review process will reduce development costs and timelines – a win-win for affordability and access that a community of stakeholders wants and needs.”
